Juice from potato cures heartburn and ulcers

Juice from potato cures heartburn and ulcers

(IANS) / 10 August 2012

Juice from the humble potato could treat gastric ulcers, thanks to its unique anti-bacterial properties, says a new research.

A Manchester University microbiology team now hopes the compound, dubbed 'potato juice' could go into production as a daily diet supplement. Inspiration came as one of the department's scientists tucked into a spud for Sunday lunch.

It led to the discovery of a key molecule which could both cure and prevent the bacteria that lives in the stomach and causes stomach ulcers and heartburn.

Uniquely, unlike with anti-biotics, the gut bug cannot develop resistance to the 'potato juice' which also does not cause any side-effects. Scientists even carried out the test on different types of potatoes -- discovering that Maris Piper and King Edward varieties worked the best.

The process to extract the as yet unnamed molecule has now been patented, with hopes it could one day be sold as a supplement similar to pro-biotic yoghurt drinks, the Daily Mail reported.

Ian Roberts, professor of microbiology at the Faculty of Life Sciences, who worked on the discovery, said: "When I first heard about the idea of using potatoes to treat stomach ulcers I have to admit I was a bit sceptical. But on another level I wasn't surprised - a lot of botanical products have very interesting compounds and we just have to find them."

"We see this 'potato juice' as a preventative measure to stop stomach ulcers developing that people would take as part of a healthy lifestyle. It could be a huge market if we can get it developed," added Roberts.

Continued here:
Juice from potato cures heartburn and ulcers

Longevity Protein Has Diabetes-Prevention Qualities

Editor's Choice Main Category: Diabetes Also Included In: Seniors / Aging Article Date: 10 Aug 2012 - 10:00 PDT

Current ratings for: Longevity Protein Has Diabetes-Prevention Qualities

More than ten years ago, Leonard Guarente, a biology professor at MIT, discovered that the protein SIRT1 had properties that boosted longevity. Since then Guarente has investigated how the protein works in several different body tissues.

In this study, Professor Guarente set out to determine what happens when the protein is missing from adipose cells, which made up body fat.

Guarente fed mice a high-fat diet and discovered that mice lacking SIRT1 started to develop metabolic disorders, such as diabetes, significantly faster than normal mice consuming a high-fat diet.

Guarente, the Novartis Professor of Biology at MIT, explained:

Results from the study indicate that medications designed to enhance SIRT1 activity may help protect against diseases associated to obesity.

The effects of SIRT1 and other sirtuin proteins were discovered by Guarente while he was studying yeast in the 1990s. According to the researchers, these proteins have been shown to help keep cells alive and healthy, coordinate a variety of hormonal networks, regulatory proteins and other genes.

In order to examine the effects of the gene more precisely, the researchers deleted the gene from organs such as the brain and liver. In earlier studies, the team found that SIRT1 protects against neurodegeneration in the brain observed in diseases, such as Alzheimer's, Parkinson's and Huntington's diseases.

SIRT1 removes acetyl groups from other proteins by modifying their activity. According to Guarente "the possible targets of this deacetylation are numerous, which is likely what gives SIRT1 its broad range of protective powers."

Original post:
Longevity Protein Has Diabetes-Prevention Qualities

'Selfish' DNA in animal mitochondria offers possible tool to study aging

ScienceDaily (Aug. 9, 2012) Researchers at Oregon State University have discovered, for the first time in any animal species, a type of "selfish" mitochondrial DNA that is actually hurting the organism and lessening its chance to survive -- and bears a strong similarity to some damage done to human cells as they age.

The findings, just published in the journal PLoS One, are a biological oddity previously unknown in animals. But they may also provide an important new tool to study human aging, scientists said.

Such selfish mitochondrial DNA has been found before in plants, but not animals. In this case, the discovery was made almost by accident during some genetic research being done on a nematode, Caenorhabditis briggsae -- a type of small roundworm.

"We weren't even looking for this when we found it, at first we thought it must be a laboratory error," said Dee Denver, an OSU associate professor of zoology. "Selfish DNA is not supposed to be found in animals. But it could turn out to be fairly important as a new genetic model to study the type of mitochondrial decay that is associated with human aging."

DNA is the material that holds the basic genetic code for living organisms, and through complex biological processes guides beneficial cellular functions. Some of it is also found in the mitochondria, or energy-producing "powerhouse" of cells, which at one point in evolution was separate from the other DNA.

The mitochondria generally act for the benefit of the cell, even though it is somewhat separate. But the "selfish" DNA found in some plant mitochondria -- and now in animals -- has major differences. It tends to copy itself faster than other DNA, has no function useful to the cell, and in some cases actually harms the cell. In plants, for instance, it can affect flowering and sometimes cause sterility.

"We had seen this DNA before in this nematode and knew it was harmful, but didn't realize it was selfish," said Katie Clark, an OSU postdoctoral fellow. "Worms with it had less offspring than those without, they had less muscle activity. It might suggest that natural selection doesn't work very well in this species."

That's part of the general quandary of selfish DNA in general, the scientists said. If it doesn't help the organism survive and reproduce, why hasn't it disappeared as a result of evolutionary pressure? Its persistence, they say, is an example of how natural selection doesn't always work, either at the organism or cellular level. Biological progress is not perfect.

In this case, the population sizes of the nematode may be too small to eliminate the selfish DNA, researchers said.

What's also interesting, they say, is that the defects this selfish DNA cause in this roundworm are surprisingly similar to the decayed mitochondrial DNA that accumulates as one aspect of human aging. More of the selfish DNA is also found in the worms as they age.

Visit link:
'Selfish' DNA in animal mitochondria offers possible tool to study aging

Posted in DNA

DNA of cancer-stricken hibakusha preserved

Saturday, Aug. 11, 2012

NAGASAKI Nagasaki University has been preserving DNA from cells extracted from cancer-stricken A-bomb survivors since 2008 in an effort to identify tumors caused by radiation exposure.

"It may become possible to find distinctive features in DNA mutated by radiation through a detailed investigation of cancer cells from hibakusha," said Masahiro Nakashima, professor of pathology at the university's Graduate School of Biomedical Sciences.

With patients' consent, both cancerous and healthy cells are extracted from the affected region. DNA and RNA are then taken from the cells, frozen at minus 80 degrees and stored in a DNA bank at the university. The work is being conducted at Nagasaki University Hospital and the Japanese Red Cross Nagasaki Genbaku Hospital.

So far, the university has collected 365 samples not enough to reveal any distinctive features of cancers related to radiation. The situation is further complicated by the city's aging atomic bomb survivors, whose average age now stands at 77 years.

Nakashima said it is necessary to "devote all energy" to the research, despite a lack of manpower.

According to a survey conducted by the Radiation Effects Research Foundation on 94,000 hibakusha in Nagasaki and Hiroshima, a high possibility exists that radiation exposure was connected to cancer in 61 percent of patients exposed to 2 or more sieverts of radiation from the A-bombings.

It has not yet proved possible, however, to identify the causes of individual cases of cancer.

On the risk of developing cancer from small amounts of radiation emitted during the Fukushima nuclear crisis, Nakashima said "the investigation may open a door to research the effects of low-level exposure."

JIJI

See the rest here:
DNA of cancer-stricken hibakusha preserved

Posted in DNA

Bob Hoskins has Parkinson’s disease, retiring from acting

(Reuters) - Veteran British actor Bob Hoskins, the star of Who Framed Roger Rabbit, said on Wednesday he had been diagnosed with Parkinson's disease and was retiring from acting.

"Bob Hoskins wishes to announce that he will be retiring from acting, following his diagnosis of Parkinson's disease last autumn. He wishes to thank all the great and brilliant people he has worked with over the years, and all of his fans who have supported him during a wonderful career," the actor's London representatives said in a statement.

"Bob is now looking forward to his retirement with his family, and would greatly appreciate that his privacy be respected at this time."

Hoskins, 69, started his career in the 1970s on British television shows such as Thick as Thieves and Rock Follies of '77 before moving into bigger film roles, such as 1980's The Long Good Friday and 1986's Mona Lisa, for which he earned a best actor Oscar nomination and won a Golden Globe award.

The Suffolk-born actor became a staple face in the British film industry, often playing Cockney-speaking characters in both comedy and drama genres with his trademark gravelly voice.

His big Hollywood break came in 1988 when he played Eddie Valiant in Who Framed Roger Rabbit, a role for which he received a Golden Globe nomination. He then went on to play roles in 1990's Mermaids and 1991's Hook.

Hoskins' most recent movie role was as one of the eight dwarves in this year's dark fairytale Snow White and the Huntsman, alongside Chris Hemsworth and Kristen Stewart.

Parkinson's disease is an incurable, degenerative neurological disorder whose sufferers include U.S. actor Michael J. Fox and former heavyweight boxing champion Muhammad Ali.

(Reporting By Piya Sinha-Roy in Los Angeles Editing by Jill Serjeant and Leslie Gevirtz)

Copyright (c) Reuters

Read more:
Bob Hoskins has Parkinson's disease, retiring from acting

Bob Hoskins has Parkinson's disease, retiring from acting

(Reuters) - Veteran British actor Bob Hoskins, the star of Who Framed Roger Rabbit, said on Wednesday he had been diagnosed with Parkinson's disease and was retiring from acting.

"Bob Hoskins wishes to announce that he will be retiring from acting, following his diagnosis of Parkinson's disease last autumn. He wishes to thank all the great and brilliant people he has worked with over the years, and all of his fans who have supported him during a wonderful career," the actor's London representatives said in a statement.

"Bob is now looking forward to his retirement with his family, and would greatly appreciate that his privacy be respected at this time."

Hoskins, 69, started his career in the 1970s on British television shows such as Thick as Thieves and Rock Follies of '77 before moving into bigger film roles, such as 1980's The Long Good Friday and 1986's Mona Lisa, for which he earned a best actor Oscar nomination and won a Golden Globe award.

The Suffolk-born actor became a staple face in the British film industry, often playing Cockney-speaking characters in both comedy and drama genres with his trademark gravelly voice.

His big Hollywood break came in 1988 when he played Eddie Valiant in Who Framed Roger Rabbit, a role for which he received a Golden Globe nomination. He then went on to play roles in 1990's Mermaids and 1991's Hook.

Hoskins' most recent movie role was as one of the eight dwarves in this year's dark fairytale Snow White and the Huntsman, alongside Chris Hemsworth and Kristen Stewart.

Parkinson's disease is an incurable, degenerative neurological disorder whose sufferers include U.S. actor Michael J. Fox and former heavyweight boxing champion Muhammad Ali.

(Reporting By Piya Sinha-Roy in Los Angeles Editing by Jill Serjeant and Leslie Gevirtz)

Copyright (c) Reuters

Read more:
Bob Hoskins has Parkinson's disease, retiring from acting

Bob Hoskins reveals he is suffering from Parkinson’s Disease as he announces retirement from acting career

His agent said Hoskins, 69, was given the diagnosis in the autumn and planned to spend time with his family Hoskins, from Suffolk in England, has played a range of roles since the 1970s, ranging from gangster films to comedy roles Parkinson's is a neurological condition which is thought to affect around 127,000 people in the UK and has no known cure

By David Wilkes

PUBLISHED: 11:06 EST, 8 August 2012 | UPDATED: 05:43 EST, 9 August 2012

Retiring: Bob Hoskins was given the diagnosis in the autumn. Announcing his retirement the star's agent said he planned to spent time with his family

Actor Bob Hoskins is retiring from showbusiness after being diagnosed with Parkinsons disease.

The announcement brings to an end a silver screen career which spanned four decades and included Hollywood hits such as Who Framed Roger Rabbit.

His most recent appearance was in Snow White and the Huntsman, released this year and starring Kristen Stewart.

Hoskins, 69, revealed his battle with the brain disorder yesterday, several months after his diagnosis.

A statement released by his agent said: 'Bob Hoskins wishes to announce that he will be retiring from acting, following his diagnosis of Parkinsons disease last autumn.

'He wishes to thank all the great and brilliant people he has worked with over the years, and all of his fans who have supported him during a wonderful career.

Read more from the original source:
Bob Hoskins reveals he is suffering from Parkinson's Disease as he announces retirement from acting career

Bob Hoskins reveals he is suffering from Parkinson's Disease as he announces retirement from acting career

His agent said Hoskins, 69, was given the diagnosis in the autumn and planned to spend time with his family Hoskins, from Suffolk in England, has played a range of roles since the 1970s, ranging from gangster films to comedy roles Parkinson's is a neurological condition which is thought to affect around 127,000 people in the UK and has no known cure

By David Wilkes

PUBLISHED: 11:06 EST, 8 August 2012 | UPDATED: 05:43 EST, 9 August 2012

Retiring: Bob Hoskins was given the diagnosis in the autumn. Announcing his retirement the star's agent said he planned to spent time with his family

Actor Bob Hoskins is retiring from showbusiness after being diagnosed with Parkinsons disease.

The announcement brings to an end a silver screen career which spanned four decades and included Hollywood hits such as Who Framed Roger Rabbit.

His most recent appearance was in Snow White and the Huntsman, released this year and starring Kristen Stewart.

Hoskins, 69, revealed his battle with the brain disorder yesterday, several months after his diagnosis.

A statement released by his agent said: 'Bob Hoskins wishes to announce that he will be retiring from acting, following his diagnosis of Parkinsons disease last autumn.

'He wishes to thank all the great and brilliant people he has worked with over the years, and all of his fans who have supported him during a wonderful career.

Read more from the original source:
Bob Hoskins reveals he is suffering from Parkinson's Disease as he announces retirement from acting career

Symptoms of Parkinson's disease

By SPECIAL TO HERNANDO | Hernando Today Published: August 09, 2012 Updated: August 09, 2012 - 1:12 PM

Parkinson's disease symptoms and signs may vary from person to person. Early signs may be mild and may go unnoticed. Symptoms often begin on one side of your body and usually remain worse on that side, even after symptoms begin to affect both sides. Parkinson's signs and symptoms may include:

Tremor. Your tremor, or shaking, usually begins in your limb, often your hand or fingers. You may notice a back-and-forth rubbing of your thumb and forefinger, known as a pill-rolling tremor. One characteristic of Parkinson's disease is tremor of your hand when it is relaxed (at rest).

Slowed movement (bradykinesia). Over time, Parkinson's disease may reduce your ability to move and slow your movement. This may make simple tasks difficult and time-consuming. Your steps may become shorter when you walk, or you may find it difficult to get out of a chair. Also, your feet may stick to the floor as you try to walk, making it difficult to move.

Rigid muscles. Muscle stiffness may occur in any parts of your body. The stiff muscles can limit your range of motion and cause you pain.

Impaired posture and balance. Your posture may have become stooped, or you may have balance problems as a result of Parkinson's disease.

Loss of automatic movements. In Parkinson's disease, you may have a decreased ability to perform unconscious movements, including blinking, smiling or swinging your arms when you walk. You may no longer gesture when talking.

Speech changes. You often may have speech problems as a result of Parkinson's disease. You may speak softly, quickly, slur or hesitate before talking. Your speech may be more of a monotone, rather than with the usual inflections.

Writing changes. Writing may appear small and become difficult.

Medications typically markedly reduce many of these symptoms. These medications increase or substitute for a specific signaling chemical (neurotransmitter) in your brain: dopamine. People with Parkinson's disease have low brain dopamine concentrations.

See the article here:
Symptoms of Parkinson's disease

Symptoms of Parkinson’s disease

By SPECIAL TO HERNANDO | Hernando Today Published: August 09, 2012 Updated: August 09, 2012 - 1:12 PM

Parkinson's disease symptoms and signs may vary from person to person. Early signs may be mild and may go unnoticed. Symptoms often begin on one side of your body and usually remain worse on that side, even after symptoms begin to affect both sides. Parkinson's signs and symptoms may include:

Tremor. Your tremor, or shaking, usually begins in your limb, often your hand or fingers. You may notice a back-and-forth rubbing of your thumb and forefinger, known as a pill-rolling tremor. One characteristic of Parkinson's disease is tremor of your hand when it is relaxed (at rest).

Slowed movement (bradykinesia). Over time, Parkinson's disease may reduce your ability to move and slow your movement. This may make simple tasks difficult and time-consuming. Your steps may become shorter when you walk, or you may find it difficult to get out of a chair. Also, your feet may stick to the floor as you try to walk, making it difficult to move.

Rigid muscles. Muscle stiffness may occur in any parts of your body. The stiff muscles can limit your range of motion and cause you pain.

Impaired posture and balance. Your posture may have become stooped, or you may have balance problems as a result of Parkinson's disease.

Loss of automatic movements. In Parkinson's disease, you may have a decreased ability to perform unconscious movements, including blinking, smiling or swinging your arms when you walk. You may no longer gesture when talking.

Speech changes. You often may have speech problems as a result of Parkinson's disease. You may speak softly, quickly, slur or hesitate before talking. Your speech may be more of a monotone, rather than with the usual inflections.

Writing changes. Writing may appear small and become difficult.

Medications typically markedly reduce many of these symptoms. These medications increase or substitute for a specific signaling chemical (neurotransmitter) in your brain: dopamine. People with Parkinson's disease have low brain dopamine concentrations.

See the article here:
Symptoms of Parkinson's disease

Bob Hoskins suffering from Parkinson’s Disease, announces retirement from acting

His agent said Hoskins, 69, was given the diagnosis in the autumn and planned to spend time with his family Hoskins, from Suffolk in England, has played a range of roles since the 1970s, ranging from gangster films to comedy roles Parkinson's is a neurological condition which is thought to affect around 127,000 people in the UK and has no known cure

By David Wilkes

PUBLISHED: 11:06 EST, 8 August 2012 | UPDATED: 05:43 EST, 9 August 2012

Retiring: Bob Hoskins was given the diagnosis in the autumn. Announcing his retirement the star's agent said he planned to spent time with his family

Actor Bob Hoskins is retiring from showbusiness after being diagnosed with Parkinsons disease.

The announcement brings to an end a silver screen career which spanned four decades and included Hollywood hits such as Who Framed Roger Rabbit.

His most recent appearance was in Snow White and the Huntsman, released this year and starring Kristen Stewart.

Hoskins, 69, revealed his battle with the brain disorder yesterday, several months after his diagnosis.

A statement released by his agent said: 'Bob Hoskins wishes to announce that he will be retiring from acting, following his diagnosis of Parkinsons disease last autumn.

'He wishes to thank all the great and brilliant people he has worked with over the years, and all of his fans who have supported him during a wonderful career.

View original post here:
Bob Hoskins suffering from Parkinson's Disease, announces retirement from acting

Bob Hoskins suffering from Parkinson's Disease, announces retirement from acting

His agent said Hoskins, 69, was given the diagnosis in the autumn and planned to spend time with his family Hoskins, from Suffolk in England, has played a range of roles since the 1970s, ranging from gangster films to comedy roles Parkinson's is a neurological condition which is thought to affect around 127,000 people in the UK and has no known cure

By David Wilkes

PUBLISHED: 11:06 EST, 8 August 2012 | UPDATED: 05:43 EST, 9 August 2012

Retiring: Bob Hoskins was given the diagnosis in the autumn. Announcing his retirement the star's agent said he planned to spent time with his family

Actor Bob Hoskins is retiring from showbusiness after being diagnosed with Parkinsons disease.

The announcement brings to an end a silver screen career which spanned four decades and included Hollywood hits such as Who Framed Roger Rabbit.

His most recent appearance was in Snow White and the Huntsman, released this year and starring Kristen Stewart.

Hoskins, 69, revealed his battle with the brain disorder yesterday, several months after his diagnosis.

A statement released by his agent said: 'Bob Hoskins wishes to announce that he will be retiring from acting, following his diagnosis of Parkinsons disease last autumn.

'He wishes to thank all the great and brilliant people he has worked with over the years, and all of his fans who have supported him during a wonderful career.

View original post here:
Bob Hoskins suffering from Parkinson's Disease, announces retirement from acting

Bob Hoskins reveals Parkinson’s disease, bows out

Veteran British actor Bob Hoskins, the star of films including Who Framed Roger Rabbit, says he has been diagnosed with Parkinson's disease and is retiring from acting.

Hoskins, 69, started his career in the 1970s on British television shows such as Thick as Thieves and Rock Follies of '77 before moving into bigger film roles, such as 1980's The Long Good Friday and 1986's Mona Lisa, for which he earned a best actor Oscar nomination and won a Golden Globe award.

"Bob Hoskins wishes to announce that he will be retiring from acting, following his diagnosis of Parkinson's disease last autumn.

"He wishes to thank all the great and brilliant people he has worked with over the years, and all of his fans who have supported him during a wonderful career," the actor's London representatives said in a statement.

"Bob is now looking forward to his retirement with his family, and would greatly appreciate that his privacy be respected at this time."

The Suffolk-born actor became a staple face in the British film industry, often playing Cockney-speaking characters in both comedy and drama genres with his trademark gravelly voice.

His big Hollywood break came in 1988 when he played Eddie Valiant in Who Framed Roger Rabbit, a role for which he received a Golden Globe nomination.

He then went on to play roles in 1990's Mermaids and 1991's Hook.

Hoskins' most recent movie role was as one of the eight dwarves in this year's dark fairytale Snow White and the Huntsman, alongside Chris Hemsworth and Kristen Stewart.

Parkinson's disease is an incurable, degenerative neurological disorder whose sufferers include US actor Michael J Fox and former heavyweight boxing champion Muhammad Ali.

The rest is here:
Bob Hoskins reveals Parkinson's disease, bows out

Bob Hoskins reveals Parkinson's disease, bows out

Veteran British actor Bob Hoskins, the star of films including Who Framed Roger Rabbit, says he has been diagnosed with Parkinson's disease and is retiring from acting.

Hoskins, 69, started his career in the 1970s on British television shows such as Thick as Thieves and Rock Follies of '77 before moving into bigger film roles, such as 1980's The Long Good Friday and 1986's Mona Lisa, for which he earned a best actor Oscar nomination and won a Golden Globe award.

"Bob Hoskins wishes to announce that he will be retiring from acting, following his diagnosis of Parkinson's disease last autumn.

"He wishes to thank all the great and brilliant people he has worked with over the years, and all of his fans who have supported him during a wonderful career," the actor's London representatives said in a statement.

"Bob is now looking forward to his retirement with his family, and would greatly appreciate that his privacy be respected at this time."

The Suffolk-born actor became a staple face in the British film industry, often playing Cockney-speaking characters in both comedy and drama genres with his trademark gravelly voice.

His big Hollywood break came in 1988 when he played Eddie Valiant in Who Framed Roger Rabbit, a role for which he received a Golden Globe nomination.

He then went on to play roles in 1990's Mermaids and 1991's Hook.

Hoskins' most recent movie role was as one of the eight dwarves in this year's dark fairytale Snow White and the Huntsman, alongside Chris Hemsworth and Kristen Stewart.

Parkinson's disease is an incurable, degenerative neurological disorder whose sufferers include US actor Michael J Fox and former heavyweight boxing champion Muhammad Ali.

The rest is here:
Bob Hoskins reveals Parkinson's disease, bows out

Research and Markets: R&D Trends: Parkinson’s Disease – Pipeline swells but a paradigm shift is unlikely in the mid-term

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/r5jrks/randd_trends_park) has announced the addition of the "R&D Trends: Parkinson's Disease - Pipeline swells but a paradigm shift is unlikely in the mid-term" report to their offering.

Review of key trends in the development of new Parkinson's disease drugs across the seven major markets. Includes detailed analyses of the composition of the pipeline, clinical trial design, target product profile, and future treatment developments.

Since early 2011, R&D efforts in Parkinson's disease have been met with mixed success. In Q1 2012, the US FDA re-approved UCB's Neupro (rotigotine patch), and accepted the New Drug Application filing for Impax/GSK's IPX066 for idiopathic Parkinson's disease. Meanwhile, the development of eight late-stage pipeline candidates has been discontinued due to lacklustre efficacy.

Scope

Highlights

Key Topics Covered:

OVERVIEW

EXECUTIVE SUMMARY

CLINICAL PIPELINE OVERVIEW

Read the original post:
Research and Markets: R&D Trends: Parkinson's Disease - Pipeline swells but a paradigm shift is unlikely in the mid-term

Research and Markets: R&D Trends: Parkinson's Disease – Pipeline swells but a paradigm shift is unlikely in the mid-term

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/r5jrks/randd_trends_park) has announced the addition of the "R&D Trends: Parkinson's Disease - Pipeline swells but a paradigm shift is unlikely in the mid-term" report to their offering.

Review of key trends in the development of new Parkinson's disease drugs across the seven major markets. Includes detailed analyses of the composition of the pipeline, clinical trial design, target product profile, and future treatment developments.

Since early 2011, R&D efforts in Parkinson's disease have been met with mixed success. In Q1 2012, the US FDA re-approved UCB's Neupro (rotigotine patch), and accepted the New Drug Application filing for Impax/GSK's IPX066 for idiopathic Parkinson's disease. Meanwhile, the development of eight late-stage pipeline candidates has been discontinued due to lacklustre efficacy.

Scope

Highlights

Key Topics Covered:

OVERVIEW

EXECUTIVE SUMMARY

CLINICAL PIPELINE OVERVIEW

Read the original post:
Research and Markets: R&D Trends: Parkinson's Disease - Pipeline swells but a paradigm shift is unlikely in the mid-term

Update on Teva’s Laquinimod – Analyst Blog

Referenced Stocks: BIIB, NVS, RRMS, SPA, TEVA

Teva Pharmaceutical Industries Ltd. ( TEVA ) and Active Biotech recently announced that they intend to commence a phase III study with their oral multiple sclerosis candidate, laquinimod. The study will be conducted under the US Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) program.

The phase III study, CONCERTO, will be conducted in patients with relapsing-remitting multiple sclerosis (RRMS). Two doses of laquinimod (0.6 mg and 1.2 mg) will be evaluated in the study for up to 24 months with the primary endpoint being confirmed disability progression as measured by the Expanded Disability Status Scale (EDSS).

Laquinimod has been evaluated in two other phase III trials (ALLEGRO and BRAVO) earlier. The candidate is also being studied for Crohn's disease and lupus.

The successful development and launch of laquinimod would help strengthen Teva's multiple sclerosis drug portfolio. Being an oral formulation, laquinimod could provide an advantage over therapies that require injection or infusion.

Teva already has a multiple sclerosis product in its portfolio - Copaxone. Copaxone is approved for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis (RRMS), including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

Teva received some good news on the Copaxone patent infringement lawsuit front recently with favorable court rulings in the UK and the US. With these rulings, Copaxone should be protected from generic competition until September 2015.

The favorable rulings are a major positive for Teva. With Copaxone contributing 19.5% to total revenues in 2011, the earlier-than-expected entry of generic versions would have been a major setback for the company. Teva can now focus on extending Copaxone's life cycle.

We are pleased with Teva's efforts to expand its multiple sclerosis franchise. The multiple sclerosis market represents significant commercial potential. The disease is estimated to affect more than 400,000 people in the US. Worldwide, it is estimated that more than two million people may be suffering from multiple sclerosis.

Key players in the multiple sclerosis market include Biogen ( BIIB ) and Novartis ( NVS ) among others.

See more here:
Update on Teva's Laquinimod - Analyst Blog

Update on Teva's Laquinimod – Analyst Blog

Referenced Stocks: BIIB, NVS, RRMS, SPA, TEVA

Teva Pharmaceutical Industries Ltd. ( TEVA ) and Active Biotech recently announced that they intend to commence a phase III study with their oral multiple sclerosis candidate, laquinimod. The study will be conducted under the US Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) program.

The phase III study, CONCERTO, will be conducted in patients with relapsing-remitting multiple sclerosis (RRMS). Two doses of laquinimod (0.6 mg and 1.2 mg) will be evaluated in the study for up to 24 months with the primary endpoint being confirmed disability progression as measured by the Expanded Disability Status Scale (EDSS).

Laquinimod has been evaluated in two other phase III trials (ALLEGRO and BRAVO) earlier. The candidate is also being studied for Crohn's disease and lupus.

The successful development and launch of laquinimod would help strengthen Teva's multiple sclerosis drug portfolio. Being an oral formulation, laquinimod could provide an advantage over therapies that require injection or infusion.

Teva already has a multiple sclerosis product in its portfolio - Copaxone. Copaxone is approved for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis (RRMS), including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

Teva received some good news on the Copaxone patent infringement lawsuit front recently with favorable court rulings in the UK and the US. With these rulings, Copaxone should be protected from generic competition until September 2015.

The favorable rulings are a major positive for Teva. With Copaxone contributing 19.5% to total revenues in 2011, the earlier-than-expected entry of generic versions would have been a major setback for the company. Teva can now focus on extending Copaxone's life cycle.

We are pleased with Teva's efforts to expand its multiple sclerosis franchise. The multiple sclerosis market represents significant commercial potential. The disease is estimated to affect more than 400,000 people in the US. Worldwide, it is estimated that more than two million people may be suffering from multiple sclerosis.

Key players in the multiple sclerosis market include Biogen ( BIIB ) and Novartis ( NVS ) among others.

See more here:
Update on Teva's Laquinimod - Analyst Blog

Update on Teva’s Laquinimod

Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech recently announced that they intend to commence a phase III study with their oral multiple sclerosis candidate, laquinimod. The study will be conducted under the US Food and Drug Administrations (:FDA) Special Protocol Assessment (SPA) program.

The phase III study, CONCERTO, will be conducted in patients with relapsing-remitting multiple sclerosis (RRMS). Two doses of laquinimod (0.6 mg and 1.2 mg) will be evaluated in the study for up to 24 months with the primary endpoint being confirmed disability progression as measured by the Expanded Disability Status Scale (:EDSS).

Laquinimod has been evaluated in two other phase III trials (ALLEGRO and BRAVO) earlier. The candidate is also being studied for Crohns disease and lupus.

The successful development and launch of laquinimod would help strengthen Tevas multiple sclerosis drug portfolio. Being an oral formulation, laquinimod could provide an advantage over therapies that require injection or infusion.

Teva already has a multiple sclerosis product in its portfolio Copaxone. Copaxone is approved for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis (RRMS), including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

Teva received some good news on the Copaxone patent infringement lawsuit front recently with favorable court rulings in the UK and the US. With these rulings, Copaxone should be protected from generic competition until September 2015.

The favorable rulings are a major positive for Teva. With Copaxone contributing 19.5% to total revenues in 2011, the earlier-than-expected entry of generic versions would have been a major setback for the company. Teva can now focus on extending Copaxones life cycle.

We are pleased with Tevas efforts to expand its multiple sclerosis franchise. The multiple sclerosis market represents significant commercial potential. The disease is estimated to affect more than 400,000 people in the US. Worldwide, it is estimated that more than two million people may be suffering from multiple sclerosis.

Key players in the multiple sclerosis market include Biogen (BIIB) and Novartis (NVS) among others.

We currently have a Neutral recommendation on Teva, which carries a Zacks #3 Rank (short-term Hold rating).

The rest is here:
Update on Teva's Laquinimod

Update on Teva's Laquinimod

Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech recently announced that they intend to commence a phase III study with their oral multiple sclerosis candidate, laquinimod. The study will be conducted under the US Food and Drug Administrations (:FDA) Special Protocol Assessment (SPA) program.

The phase III study, CONCERTO, will be conducted in patients with relapsing-remitting multiple sclerosis (RRMS). Two doses of laquinimod (0.6 mg and 1.2 mg) will be evaluated in the study for up to 24 months with the primary endpoint being confirmed disability progression as measured by the Expanded Disability Status Scale (:EDSS).

Laquinimod has been evaluated in two other phase III trials (ALLEGRO and BRAVO) earlier. The candidate is also being studied for Crohns disease and lupus.

The successful development and launch of laquinimod would help strengthen Tevas multiple sclerosis drug portfolio. Being an oral formulation, laquinimod could provide an advantage over therapies that require injection or infusion.

Teva already has a multiple sclerosis product in its portfolio Copaxone. Copaxone is approved for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis (RRMS), including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.

Teva received some good news on the Copaxone patent infringement lawsuit front recently with favorable court rulings in the UK and the US. With these rulings, Copaxone should be protected from generic competition until September 2015.

The favorable rulings are a major positive for Teva. With Copaxone contributing 19.5% to total revenues in 2011, the earlier-than-expected entry of generic versions would have been a major setback for the company. Teva can now focus on extending Copaxones life cycle.

We are pleased with Tevas efforts to expand its multiple sclerosis franchise. The multiple sclerosis market represents significant commercial potential. The disease is estimated to affect more than 400,000 people in the US. Worldwide, it is estimated that more than two million people may be suffering from multiple sclerosis.

Key players in the multiple sclerosis market include Biogen (BIIB) and Novartis (NVS) among others.

We currently have a Neutral recommendation on Teva, which carries a Zacks #3 Rank (short-term Hold rating).

The rest is here:
Update on Teva's Laquinimod